KM Research Hub
← 返回论文库
待处理 入排:符合 图源:待检查 入排置信度 0.95

Capivasertib plus abiraterone in PTEN-deficient de novo metastatic hormone-sensitive prostate cancer: updated survival analysis from CAPItello-281.

K Fizazi, N W Clarke, M De Santis, H Uemura, A P Fay, N Karadurmus, C Alvarez-Fernandez, S Jiang, D Parslow, M Sotelo, Y Ürün, N Oliveira, T Gyun Kwon, M Özgüroğlu, G Roubaud, D Castellano, J K Logan, T Morris, C Gresty, D J George

Ann Oncol S0923-7534(26)06878-X

PMID42918424
PMCID-
DOI10.1016/j.annonc.2026.10.097
发表日期2026-10-23
入排依据:Eligible updated Phase III randomized drug trial report in human prostate cancer with OS/rPFS time-to-event efficacy results.
摘要

摘要

BACKGROUND: Patients with phosphatase and tensin homolog (PTEN)-deficient de novo metastatic hormone-sensitive prostate cancer (mHSPC) have poor prognosis and reduced benefit from current standard of care. The phase III CAPItello-281 study (NCT04493853) showed a statistically significant benefit in radiographic progression-free survival (rPFS) with capivasertib plus abiraterone versus placebo plus abiraterone (combined with prednisone/prednisolone and androgen deprivation therapy): hazard ratio (HR) 0.81, 95% confidence interval (CI) 0.66-0.98; P = 0.034. The HR for interim overall survival (OS; 26% maturity) was 0.90, 95% CI 0.71-1.15. Here, we report ad hoc, descriptive analyses at 42% OS data maturity. PATIENTS AND METHODS: Patients with de novo mHSPC and PTEN-deficient tumors (defined as ≥90% of viable malignant cells with no specific cytoplasmic staining by immunohistochemistry) received capivasertib plus abiraterone or matched placebo (randomly assigned 1 : 1) plus abiraterone. Analyses carried out at this ad hoc data cut-off, including the alpha-controlled key secondary endpoint of OS as well as the primary endpoint of investigator-assessed rPFS, were descriptive and not prespecified in the protocol. RESULTS: A total of 1012 patients received capivasertib plus abiraterone (n = 507) or placebo plus abiraterone (n = 505). At this ad hoc analysis at 42% OS maturity (data cut-off: 9 March 2026), with 17 months' additional follow-up (median follow-up 39 months in both arms), HR for OS favored capivasertib plus abiraterone versus placebo plus abiraterone (HR 0.82, 95% CI 0.68-0.99, P = 0.044) and OS medians were reached: 57.4 versus 46.5 months. Updated rPFS (HR 0.83, 95% CI 0.70-0.99, nominal P = 0.033; median 35.5 versus 26.0 months) was consistent with the primary analysis. The safety profile remained consistent with the primary findings. CONCLUSIONS: With longer follow-up, findings from this updated descriptive analysis support the clinically meaningful OS benefit of adding capivasertib to abiraterone in the treatment of patients with PTEN-deficient mHSPC. Capivasertib plus abiraterone represents a first-in-class targeted treatment approach for this poor prognosis population with high unmet need.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。